Antibiotic reimbursement in a model delinked from sales: A benchmark-based worldwide approach

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages 500-505

  Rex, John H ^a,b,c   Outterson, Kevin ^d,e  

^a ASTRAZENECA   (United Kingdom)

^b F2G LTD   (United Kingdom)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NOVOBIOCIN; ANTIINFECTIVE AGENT;

CLINICAL EFFECTIVENESS; DRUG COST; DRUG MARKETING; HEALTH INSURANCE; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REIMBURSEMENT; COMMERCIAL PHENOMENA; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; HEALTH CARE DELIVERY; QUALITY CONTROL; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; BENCHMARKING; COMMERCE; DELIVERY OF HEALTH CARE; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, THEORETICAL; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84962510658     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00500-9     Document Type: Review

References (35)

1. Boucher HW, Talbot GH, Benjamin DK, et al. 10×'20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:1685-1694. the Infectious Diseases Society of America.
2. Antibiotic resistance threats in the United States Centers for Disease Control and Prevention, (accessed Feb 1, 2016). http://www.cdc.gov/drugresistance/threat-report-2013/.
3. Morel CM, Mossialos E Stoking the antibiotic pipeline. BMJ 2010, 340:c2115.
4. Outterson K, Powers JH, Daniel GW, McClellan MB Repairing the broken market for antibiotic innovation. Health Aff (Millwood) 2015, 34:277-285.
5. Payne DJ, Miller LF, Findlay D, Anderson J, Marks L Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci 2015, 370:20140086.
6. Rex JH ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 2014, 12:231-232.
7. So AD, Gupta N, Brahmachari SK, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat 2011, 14:88-94.
8. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013, 13:269-275.
9. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. CDER United States Food & Drug Administration, (accessed July 1, 2013). http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm359184.pdf.
10. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), (accessed May 1, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf.
11. Sertkaya A, Eyraud J, Birkenbach A, et al. Analytical framework for examining the value of antibacterial products. Report to United States Department of Health and Human Services (accessed June 17, 2014). http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.
12. Projan SJ Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol 2003, 6:427-430.
13. Kinch MS, Patridge E, Plummer M, Hoyer D An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov Today 2014, 19:1283-1287.
14. Löfmark S, Sjöström K, Mäkitalo B, et al. Carbapenemase-producing Enterobacteriaceae in Sweden 2007-2013: experiences from seven years of systematic surveillance and mandatory reporting. Drug Resist Updat 2015, 20:29-38.
15. National strategy for combating antibiotic-resistant bacteria The White House, (accessed May 1, 2015). https://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf.
16. Outterson K New business models for sustainable antibiotics. Chatham House (accessed March 2, 2014). http://www.chathamhouse.org/publications/papers/view/197446.
17. Clift C, Gopinathan U, Morel C, Outterson K, Røttingen J-A, So A Towards a new global business model for antibiotics: delinking revenues from sales. Chatham House (accessed Nov 3, 2015). https://www.chathamhouse.org/publication/towards-new-global-business-model-antibiotics-delinking-revenues-sales.
18. Sharma P, Towse A New drugs to tackle antimicrobial resistance: analysis of EU policy options. Office of Health Economics, London (accessed Feb 1, 2016). http://www.ohe.org/publications/article/new-drugs-to-tackle-antimicrobial-resistance-analysis-of-eu-policy-options-21.cfm.
19. Securing new drugs for future generations: the pipeline of antibiotics Review on antimicrobial resistance, (accessed Feb 1, 2016). http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf.
20. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS Approval and withdrawal of new antibiotics and other antiinfectives in the US, 1980-2009. J Law Med Ethics 2013, 41:688-696.
21. Outterson K, Pogge T, Hollis A Combating antibiotic resistance through the Health Impact Fund. The globalization of health care: legal and ethical issues 2013, 318-341. Oxford University Press, Oxford. I.G. Cohen (Ed.).
22. McClellan M Accountable care organizations and evidence-based payment reform. JAMA 2015, 313:2128-2130.
23. Burns JF Thousands flee Indian city in deadly plague outbreak. The New York Times Sept 24, 1994, (accessed May 5, 2015). http://www.nytimes.com/1994/09/24/world/thousands-flee-indian-city-in-deadly-plague-outbreak.html.
24. The Black Death revisited: India's 1994 plague epidemic. World Resources 1996-1997 The World Resource Institute, The United Nations Environment ProgrammeThe United Nations Environment Programme, The United Nations Development ProgrammeThe United Nations Development Programme, the World Bankthe World Bank, (accessed May 5, 2015). http://www.rrojasdatabank.info/uh_b3.htm.
25. Jaczynska E, Outterson K, Mestre-Ferrandiz J Business model options for antibiotics: learning from other industries. Chatham House (accessed May 1, 2015). http://drive-ab.eu/wp-content/uploads/2014/09/Business-Model-Options-for-Antibiotics-learning-from-other-industries.pdf.
26. COM Staff and WSMV-TV. Firefighters let home burn over $75 fee-again MSNBC, (accessed Nov 3, 2015). http://usnews.nbcnews.com/_news/2011/12/07/9272989-firefighters-let-home-burn-over-75-fee-again.
27. Martin TW Putting out fires for a fee: volunteer departments get taxes, but some insist that residents pay more (accessed Nov 3, 2015). http://www.wsj.com/articles/SB10001424052970203961204577269591267553530.
28. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012, 91:426-437.
29. Report on safer healthcare in Europe: improving patient safety and fighting antimicrobial resistance (2014/2207(INI)). A8-0142/2015 (see point 78) European Parliament, (accessed March 1, 2016). http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P8-TA-2015-0197+0+DOC+XML+V0//EN.
30. Bisacchi GS, Manchester JI A new-class antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV. ACS Infect Dis 2015, 1:4-41.
31. Ellenberg SS, Temple R Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000, 133:464-470.
32. Hoffman SJ, Outterson K, Røttingen JA, et al. An international legal framework to address antimicrobial resistance. Bull World Health Organ 2015, 93:66.
33. Årdal C, Outterson K, Hoffman SJ, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet 2015, published online Nov 18. 10.1016/S0140-6736(15)00470-5.
34. Hoffman SJ, Outterson K INTRODUCTION: What will it take to address the global threat of antibiotic resistance?. J Law Med Ethics 2015, 43(suppl 3):6-11.
35. Cohen ML Changing patterns of infectious disease. Nature 2000, 406:762-767.